Search
Calidi Biotherapeutics Inc
CLDIAdd to Watchlist
0.149USD
-0.010-6.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.03MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-6.46%
5 Days
-8.65%
1 Month
-14.37%
6 Months
-87.37%
Year to Date
-87.26%
1 Year
-94.95%
Key Figures
0.154Open
0.155High
3.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
44.37%Turnover Ratio
0.158Prev. Close
0.147Low
312.78KTurnover
LossP/E Static
0.15P/B
0.00%Div Yield TTM
-155.01%ROA
19.20052wk High
0.71Volume Ratio
-23.81MNet Profit
6.91MShares
-4.1654EPS TTM
1.52Beta
-421.19%ROE
0.20952wk Low
4.94%Amplitude
68.89%Gross Margin
1.03MMarket Cap
-1.35Reward/Risk
6.80%Risk Rate
TradingKey Stock Score of Calidi Biotherapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Calidi Biotherapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 243 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Calidi Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Calidi Biotherapeutics Inc Highlights
StrengthsRisks
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Overvalued
The company’s latest PE is -0.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 712.13K shares, increasing 31.33% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+4247.83%
Upside Space
Calidi Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Calidi Biotherapeutics Inc Info
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Ticker SymbolCLDI
CompanyCalidi Biotherapeutics Inc
CEOPoma (Eric)
Websitehttps://www.calidibio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Calidi Biotherapeutics Inc (CLDI)?
The current price of Calidi Biotherapeutics Inc (CLDI) is 0.15.
What is the symbol of Calidi Biotherapeutics Inc?
The ticker symbol of Calidi Biotherapeutics Inc is CLDI.
What is the 52-week high of Calidi Biotherapeutics Inc?
The 52-week high of Calidi Biotherapeutics Inc is 19.20.
What is the 52-week low of Calidi Biotherapeutics Inc?
The 52-week low of Calidi Biotherapeutics Inc is 0.21.
What is the market capitalization of Calidi Biotherapeutics Inc?
The market capitalization of Calidi Biotherapeutics Inc is 1.03M.
Is Calidi Biotherapeutics Inc (CLDI) currently rated as Buy, Hold, or Sell?
According to analysts, Calidi Biotherapeutics Inc (CLDI) has an overall rating of STRONG BUY, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of Calidi Biotherapeutics Inc (CLDI)?
The Earnings Per Share (EPS TTM) of Calidi Biotherapeutics Inc (CLDI) is -5.95.